Related Experiment Video
Updated: Apr 28, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Genome-Wide Histone Acetylation Underlies Tumor Intrinsic Immune Signaling Induced by Photothermal Therapy in Ovarian
Reddick R Walker1,2, Melissa Hadley1,2, Jose Colina1,2
1The George Washington University Cancer Center, Washington, D.C., USA.
Abstract:
Ovarian cancers (OCs) remain a lethal gynecological malignancy characterized by an immunosuppressive tumor microenvironment lacking effector lymphocytes. Thus, increasing tumor intrinsic immune signaling in OC remains a therapeutic goal for improving recruitment and activation of lymphocytes to the tumor microenvironment. A nanoparticle-based thermal treatment, Prussian blue nanoparticle photothermal therapy (PBNP-PTT), has shown strong antigen-specific lymphocyte recruitment to the tumor microenvironment through induction of immunogenic cell death in preclinical tumor models. Therefore, this study sought to determine the efficacy of PBNP-PTT in OC cell lines. We first demonstrate that PBNP-PTT induced tumor intrinsic immune signaling in OC cells and led to improved monocyte activation through tumor intrinsic proinflammatory cytokine release and presentation of damage-associated molecular patterns. Accompanying this intrinsic immunostimulatory effect, we report a novel epigenetic hallmark response to PBNP-PTT characterized by genome-wide H3K9 acetylation. Finally, increasing histone acetylation via histone deacetylase inhibition (Panobinostat) improved the tumor intrinsic immune signaling potential of PBNP-PTT. These findings indicate that PBNP-PTT activates the release of immunostimulatory factors in ovarian cancer cells alongside H3K9ac rewiring and suggests the potential of combining PBNP-PTT with HDACi to improve tumor intrinsic immune signaling in ovarian cancer.
More Related Videos
Related Concept Videos
Spreading of Chromatin Modifications
Writers
The writer...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

